Why the study?
What is the prevalence of anti-HAV antibody in HIV-positive persons compared to HIV-negative controls, and how does it vary by route of HIV exposure?
What is the prevalence of anti-HAV antibody in HIV-positive persons compared to HIV-negative controls, and how does it vary by route of HIV exposure?
HIV-positive individuals, particularly injecting drug users, have a significantly higher prevalence of anti-HAV antibodies, suggesting that targeted HAV vaccination strategies should vary by route of HIV exposure.
Answers are grounded in this paper and cite their sources.
Higher anti-HAV seroprevalence in HIV-positive persons may support targeted vaccination; leaves open whether strategies vary by exposure route.
OBJECTIVES: To retrospectively determine the prevalence of anti-hepatitis A virus (HAV) antibody in HIV-positive persons with different routes of HIV exposure and to describe its characteristics in order to guide vaccination policy. METHODS: The prevalence of anti-HAV antibody was compared between 1580 HIV-positive persons seeking medical attention and 2581 HIV-negative controls seeking health check-ups, who had undergone anti-HAV tests between 2004 and 2007. Comparisons were also made among groups of the HIV-positive patients who had acquired HIV via different routes of transmission. A multivariate logistic regression model was built to identify independent variables associated with anti-HAV seropositivity. RESULTS: The overall prevalence of anti-HAV antibody was 60.9% in the HIV-positive and 48.0% in the controls (p<0.001). The overall adjusted odds ratio (AOR) for positive anti-HAV antibody was 2.604 (95% confidence interval (CI) 2.106-3.219) in HIV-positive persons compared with HIV-negative persons. In addition, HIV-positive men who have sex with men (MSM), heterosexuals, and injecting drug users (IDU) all had significantly higher AOR for positive anti-HAV antibody than HIV-negative persons. In HIV-positive persons, older age (AOR 1.284, 95% CI 1.246-1.322) and IDU (AOR 5.137, 95% CI 3.499-7.542) were independently associated with an increased prevalence of anti-HAV antibody. Nearly 90% of the IDU had become seropositive for HAV after age 36-40 years, compared with heterosexuals and MSM after age 46-50 years, and controls after age 51-55 years. CONCLUSION: Our findings suggest that age groups to be targeted for HAV vaccination vary with the different routes of HIV exposure.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: